Host: |
HEK293 |
Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human Neuroligin-3-protein was developed from hek293. For use in research applications. |
Conjugation: |
Unconjugated |
Formulation: |
Lyophilised from 0.2 Mu m filtered PBS solution, pH7.2, 5% Trehalose. |
Storage Instruction: |
Can be stored in working aliquots at 2°C-8°C C for one month, or at-20°C to-70°C for 1 year. Avoid repeated freeze/thaw cycles. NA |
Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
Gene Symbol: |
NLGN3 |
Gene ID: |
54413 |
Uniprot ID: |
NLGN3_HUMAN |
Immunogen Region: |
GLN38-SER689 |
Immunogen: |
Optimized DNA sequence encoding I extracellular domain of Human Neuroligin-3 (NL3 ) (GLN38-SER689 ) including a C-terminal His tag was expressed in HEK293 cells. NA |
Tissue Specificity | Expressed in the blood vessel walls (at protein level). Detected in throughout the brain and in spinal cord. Detected in brain, and at lower levels in pancreas islet beta cells. |
Function | Cell surface protein involved in cell-cell-interactions via its interactions with neurexin family members. Plays a role in synapse function and synaptic signal transmission, and may mediate its effects by clustering other synaptic proteins. May promote the initial formation of synapses, but is not essential for this. May also play a role in glia-glia or glia-neuron interactions in the developing peripheral nervous system. |
Protein Name | Neuroligin-3Gliotactin Homolog |
Database Links | Reactome: R-HSA-6794361 |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinSynapseDetected At Both Glutamatergic And Gabaergic Synapses |
Alternative Protein Names | Neuroligin-3 proteinGliotactin Homolog proteinNLGN3 proteinKIAA1480 proteinNL3 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance